CN121130116A - 治疗癌症的方法 - Google Patents

治疗癌症的方法

Info

Publication number
CN121130116A
CN121130116A CN202510991495.7A CN202510991495A CN121130116A CN 121130116 A CN121130116 A CN 121130116A CN 202510991495 A CN202510991495 A CN 202510991495A CN 121130116 A CN121130116 A CN 121130116A
Authority
CN
China
Prior art keywords
compound
cancer
formula
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510991495.7A
Other languages
English (en)
Chinese (zh)
Inventor
A·A·阿穆尔
R·梅斯曼
迈克·萨瑟克格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endocyte Inc
Original Assignee
Endocyte Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endocyte Inc filed Critical Endocyte Inc
Publication of CN121130116A publication Critical patent/CN121130116A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202510991495.7A 2018-09-21 2019-09-20 治疗癌症的方法 Pending CN121130116A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862734649P 2018-09-21 2018-09-21
US62/734649 2018-09-21
PCT/US2019/052161 WO2020061458A1 (en) 2018-09-21 2019-09-20 Methods of treating cancer
CN201980077048.3A CN113164631A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980077048.3A Division CN113164631A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Publications (1)

Publication Number Publication Date
CN121130116A true CN121130116A (zh) 2025-12-16

Family

ID=69887889

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202510991495.7A Pending CN121130116A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN201980077048.3A Pending CN113164631A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991492.3A Pending CN121338051A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991493.8A Pending CN121154858A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN201980077048.3A Pending CN113164631A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991492.3A Pending CN121338051A (zh) 2018-09-21 2019-09-20 治疗癌症的方法
CN202510991493.8A Pending CN121154858A (zh) 2018-09-21 2019-09-20 治疗癌症的方法

Country Status (9)

Country Link
US (1) US20220125957A1 (https=)
EP (1) EP3852816A4 (https=)
JP (2) JP2022501441A (https=)
KR (1) KR20210095620A (https=)
CN (4) CN121130116A (https=)
AU (2) AU2019345320B2 (https=)
CA (1) CA3112806A1 (https=)
IL (2) IL281600B2 (https=)
WO (1) WO2020061458A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3533473A3 (en) 2013-11-14 2019-12-18 Endocyte, Inc. Compounds for positron emission tomography
CN112368024A (zh) 2018-04-17 2021-02-12 恩多塞特公司 治疗癌症的方法
CN114096264B (zh) 2019-05-20 2025-03-14 因多塞特股份有限公司 制备psma缀合物的方法
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
EP4178628A4 (en) 2020-07-13 2025-04-02 Point Biopharma, Inc. RADIOPHARMACEUTICALS AND PROCEDURES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154702A1 (en) * 2012-11-30 2014-06-05 Endocyte, Inc. Methods For Treating Cancer Using Combination Therapies
EP3456700A1 (en) * 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
IL237525A (en) * 2015-03-03 2017-05-29 Shalom Eli Method for labeling a prostate-specific membrane antigen with a radioactive isotope
EP3400229B1 (en) * 2016-01-10 2024-03-06 Provincial Health Services Authority 18/19f-labelled compounds which target the prostate specific membrane antigen
WO2018108287A1 (en) * 2016-12-15 2018-06-21 The European Atomic Energy Community (Euratom), Represented By The European Commission Treatment of pmsa expressing cancers
US20200297877A1 (en) * 2017-12-13 2020-09-24 Sciencons AS Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide

Also Published As

Publication number Publication date
KR20210095620A (ko) 2021-08-02
WO2020061458A1 (en) 2020-03-26
AU2019345320A1 (en) 2021-04-22
JP2022501441A (ja) 2022-01-06
AU2019345320B2 (en) 2025-12-11
IL323981A (en) 2025-12-01
AU2026201845A1 (en) 2026-04-02
EP3852816A4 (en) 2022-07-13
CN121154858A (zh) 2025-12-19
JP2024178159A (ja) 2024-12-24
EP3852816A1 (en) 2021-07-28
IL281600B1 (en) 2025-11-01
CA3112806A1 (en) 2020-03-26
US20220125957A1 (en) 2022-04-28
CN121338051A (zh) 2026-01-16
IL281600A (en) 2021-05-31
CN113164631A (zh) 2021-07-23
IL281600B2 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
US20250235466A1 (en) Methods of treating cancer
AU2019345320B2 (en) Methods of treating cancer
JP7748438B2 (ja) シールド剤およびそれらの使用
JP7447300B2 (ja) 放射性金属と複合するＤＺ－１－Ｌｙｓ－ＤＯＴＡコンジュゲート及び使用
KR20260040237A (ko) Psma 표적 방사성 리간드 치료 요법
RU2825637C2 (ru) Способы лечения рака
RU2811406C2 (ru) Способы лечения рака
TW202241450A (zh) 放射性標記的αｖβ３及／或αｖβ５整合素拮抗物的醫藥組合物的用途及使用其之方法
HK40047004A (en) Methods of treating cancer
AU2023262181A1 (en) Combination treatment of small-cell lung cancer
IL324525A (en) Methods for treating sstr-positive cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination